Company* (Country, Symbol) | Company* (Country, Symbol) | Type/Product Area | Terms/Details (Date) |
|
Abgenix Inc. (ABGX) | CuraGen Corp. (CRGN) | Strategic alliance expanded to develop and test up to 250 fully human antibody therapeutic candidates using XenoMouse and functional genomics technologies | Original agreement was for 120 candidates to treat metabolic diseases, cancer, inflammation and autoimmune disorders; Abgenix will make an equity investment in CuraGen totaling $50M; each company expects to invest an additional $100M in support of the collaboration (11/28) |
|
Abgenix Inc. (ABGX) | Immunex Corp. (IMNX) | Multiyear collaboration to discover, develop and commercialize fully human monoclonal antibodies to treat cancer | Each company will contribute five cancer-specific antigen targets during the first five years, sharing their technologies; the companies will share equally in development and commercialization of any product (11/28) |
|
Acadia Pharmaceuticals Inc.* | Allergan Inc. (NYSE:AGN) | Extension of functional genomics collaboration formed in Sept. 1997 | Acadia and Allergan extended their collaboration for two years to study AGN 195795 for glaucoma in the clinic (10/31) |
|
Aclara BioSciences Inc. (ACLA) | Zeptosens AG* (Switzerland) | Exclusive license agreement for access to microfluidics intellectual property | Financial terms were not disclosed (11/3) |
|
Alchemia Pty Ltd.* (Australia) | Dow Chemical Co. (NYSE:DOW) | Joint venture to make complex carbohydrates in commercial quantities for clinical use or biotechnology research | Alchemia will receive an up-front payment plus milestone payments, as well as half of all profits (12/6**) |
|
Amarin Corp. plc (UK; AMRN) | Laxdale Ltd.* | Licensing agreement for LAX-101 to treat Huntington's disease | Agreement includes an up-front payment in cash and stock to Laxdale, future milestone payments and royalties (11/27) |
|
Amersham Pharmacia Biotech* | BioImage AS* (Denmark) | Collaboration to commercialize a new cell-based screening technology based on green fluorescent protein | Amersham Pharmacia gains an exclusive license to BioImage's European patent portfolio on GFP, including the right to sublicense the technology (12/18) |
|
Amgen Inc. (AMGN) | Oxford Asymmetry International plc (UK; unit of Evotec Biosystems AG; Neuer Markt:EVT) | Collaborative agreement for OAI chemists to provide Amgen with discovery chemistry services | The #1.8M (US$2.6M) agreement includes fees for services and future milestone payments (12/7) |
|
Applied Molecular Evolution Inc. (AMEV) | Biosynexus Inc.* | Collaboration to develop an optimized prophylactic agent for staphylococcus bacterial infection in neonatal and pediatric populations | AME will receive research and development funding, milestone payments and royalties (12/20) |
|
Arakis Ltd.* (UK) | Vectura Ltd.* | Collaboration to develop an inhaled formulation for AD237 to treat chronic pulmonary disease | Companies will share development costs and revenues (11/29) |
|
ArQule Inc. (ARQL) | Acadia Pharmaceuticals Inc.* | Drug discovery collaboration to to discover novel small-moleculedrug candidates directed at individual G protein-coupled receptor targets | Companies will share intellectual property resulting from the collaboration and will equally contribute to at least one joint drug discovery program; they also will share revenues resulting from commercialization of any products (12/19) |
|
Array BioPharma Inc.* | Amgen Inc. (AMGN) | Research and license agreement to identify and optimize small-molecule inhibitors | Companies will collaborate to optimize small-molecule inhibitors to the phosphatase target, PTPIB, to treat diabetes and related diseases; Array will provide Amgen with an exclusive license to Array's existing PTBIB program and exclusive worldwide rights to develop and commercialize PTPIB-related products (11/1) |
|
Arrow Therapeutics Ltd.* (UK) | Virogen Ltd.* (UK) | Discovery and development agreement for respiratory syncytial virus therapies | Each company will fund its own research and will share revenues generated (12/1) |
|
Aurora Biosciences Corp. (ABSC) | Senomyx Inc.* | Exclusive collaborative research and license agreement for the discovery of consumer products enhancing taste and olfaction | Aurora will employ its green fluorescent protein technology and beta-lactamase technology to develop screening platforms for Senomyx and will conduct high-through-put screening; agreement includes an up-front technology access fee, research funding and performance milestones; Aurora purchased 1M shares of Senomyx's Series C preferred stock for $4.8M (11/1) |
|
Biogen Inc. (BGEN) | NsGene AS* (Denmark) | Option license exercised for Neublastin | Biogen will pay an up-front fee for the license and will pay NsGene $20M in fees and milestone payments upon commercialization of the neurodegenerative disease therapeutic (12/6) |
|
Biota Holdings Ltd. (Australia; ASX:BTA) | Vapotronics Ltd.* | Agreement to research the effectiveness of aerosol applications | The companies will research the applications for one or more of Biota's drugs (10/31) |
|
Biovation Ltd.* (Scotland) | Viragen Inc. (AMEX:VRA) and Procyon Biopharma Inc. (Canada; TSE:PBP) | Partnerships to use Biovation's DeImmunisation technology to develop therapeutic monoclonal antibodies | Biovation will receive research revenues, milestone payments and royalties (11/20) |
|
BioVisioN GmbH & Co. KG* (Germany) | Matrix Science Ltd.* (UK) | Long-term strategic alliance focused on developing bioinformatics technologies | The companies will combine their technologies in human peptide research and software for protein identification (12/6) |
|
British Biotech (UK; LSE:BBG; BBIOY) | BresaGen Ltd. (Australia; ASX:BGN) | Collaboration to develop and commercialize E21R for acute myeloid leukemia | British Biotech will make an equity investment of US$1M in BresaGen by issuing 1.1M new shares; it also will make up-front and milestone payments totaling US$7M; milestone payments could include another US$6M if E21R is developed for other indications; the deal also includes royalties (12/20) |
|
Celera Genomics (NYSE:CRA) | Diversa Corp. (DVSA) | Collaborative agreement to sequence the genomes and discover the genes of selected, uncultured microorganisms | Companies will focus on genes contained in Diversa's environmental libraries; financial terms were not disclosed (12/5) |
|
Celera Genomics (NYSE:CRA) | Lion Bioscience AG (Germany; Neuer Markt: LIO; LEON) | Strategic alliance to develop and deliver new software tools through the Celera Discovery System | The companies will collaborate to create improved software tools by further developing and customizing the Lion SRS system and developing new technologies (11/9) |
|
Cell Genesys Inc. (CEGE) | Xenogen Corp.* | Evaluation license agreement giving Cell Genesys access to Xenogen's in vivo imaging technologies | Cell Genesys will use the technology to develop cancer gene therapies (12/21) |
|
Compugen Inc. (unit of Compugen Ltd.; CGEN) | Motorola Inc. (NYSE:MOT) | Development and manufacturing agreement for DNA biochips | Motorola Life Sciences will develop and manufacture a number of DNA biochips using Compugen's chip design services (11/28) |
|
Crucell NV (Netherlands; CRXL) | Eurogene Ltd.* (UK) | Licensing agreement for access to the PER.C6 technology | Eurogene will license the adenoviral packaging cell line for research purposes, with an option to convert to a commercial license within five years; Crucell will receive an up-front payment with further annual payments along with royalties on net sales (12/18) |
|
Cubist Pharmaceuticals Inc. (CBST) | Emisphere Technologies Inc. (EMIS) | Research and development collaboration to use Emisphere's oral drug delivery technology for Cubist's product Cidecin and other lipopeptides | Emisphere could receive fees, research funding and milestone payments totaling $30M if a product is commercialized; Emisphere also would receive a potential royalty on sales; Cubist would be responsible for drug development and would receive exclusive worldwide commercialization rights to any oral products (11/6) |
|
Cubist Pharmaceuticals Inc. (CBST) | International Health Management Associates Inc.* | Acquisition of worldwide rights to oral ceftriaxone | Cubist acquired the rights to oral ceftriaxone, the first orally active version of the intravenous antibiotic, Rocephin; terms were ND (11/27) |
|
Cyclacel Ltd.* (Scotland) | CV Therapeutics Inc. (CVTX) | Agreement to determine the cancer-inhibition potential of CV's small-molecule compounds | Cyclacel will screen a library of compounds and also obtained the right to negotiate exclusive worldwide development and commercialization licenses for some compounds (12/5) |
|
D-Pharm Ltd.* (Israel) | Nycomed Amersham plc (UK; NYSE:NYE; LSE:NAM) | Research collaboration to discover novel imaging agents | D-Pharm will apply its lipid vector technology to early stage compounds discovered by Nycomed (11/21) |
|
Epimmune Inc. (EPMN) | Valentis Inc. (VLTS) | Licensing agreement for Valentis' PINC gene delivery technology | Epimmune will use PINC for its DNA vaccines against HIV and hepatitis C virus; non-exclusive license is in exchange for undisclosed up-front, milestone and royalty payments (12/4) |
|
Gemini Genomics plc (GMNI) | Genmab AS (Denmark; CSE:GEN) | Collaboration to develop products for osteoporosis, cardiovascular disease, diabetes and obesity | Companies equally will share product rights and costs (12/6) |
|
Gene Logic Inc. (GLGC) | Biogen Inc. (BGEN) | Agreement to supply a gene expression database | Gene Logic will construct a customized database of gene expression data derived from its GeneExpress Suite (12/21) |
|
Genencor International (GCOR) | Danisco AS* | Four-year agreement for the discovery, development and production of bioingredients for use in the food industry | Genencor and Danisco entered into an agreement that provides up to $20M in funding for Genencor's research and development efforts (10/31) |
|
Genentech Inc. (NYSE:DNA) | Actelion Ltd. (Switzerland; SWX:ATLN) | Agreement for the development and co-promotion of Actelion's endothelin receptor antagonist Tracleer (bosentan) in the U.S. | Both companies will be involved in the marketing and promotion of Tracleer, with Actelion taking the lead in the development efforts and commercialization; deal includes an up-front fee of $35M, as well as milestone payments that could make the deal worth $140M (12/13) |
|
GenOdyssee SA* (France) | UroGene SA* (France) | Two-year research collaboration for the discovery of single nucleotide polymorphisms that indicate a pre-disposition to prostate cancer | UroGene will provide GenOdyssee with a list of relevant candidate genes for studying genetic predisposition to prostate cancer in the male population; UroGene will pay fees and milestones, as well as royalties (11/15**) |
|
Genome Therapeutics Corp. (GENE) | Interleukin Genetics Inc. (ILGN) | Commercial research program to provide DNA sequencing information | The program will focus on key genes in the chromosomal region of 2q13, which may be associated with risk for inflammatory diseases; Genome will use its GTC Sequencing Center and the contract includes gene discovery and bacterial artificial chromosome screening across the interleukin-1 region; financial terms were ND (11/15) |
|
Genzyme Transgenics Corp. (GZTC) | ImmunoGen Inc. (IMGN) | Agreement for GTC to produce the humanized monoclonal antibody, huN901, in goat milk | ImmunoGen will use the antibody in its tumor-activated prodrug huN901-DMI/BB-10901, being developed to treat small-cell lung cancer (11/29) |
|
Human Genome Sciences Inc. (HGSI) | Cambridge Antibody Technology plc (UK; LSE:CAT) | Extended collaboration agreement for development of B-Lymphocyte Stimulator (BLyS), a protein discovered by HGS | Companies studied BLyS, which may serve as a treatment for autoimmune and neoplastic disorders, as part of their August 1999 pact; CAT will be entitled to receive license fees, clinical development milestones and royalties on product sales; financial details were ND (10/30) |
|
Immunex Corp. (IMNX) | Cambridge Antibody Technology plc (UK; LSE:CAT) | Partnership for phage display library access and eight exclusive therapeutic antibody product options | Agreement includes a license fee, milestone and royalty payments to CAT in exchange for CAT's antibody library for reagent generation and target validation, and eight options to develop MAbs (12/1) |
|
Immuno-Designed Molecules* (France) | Medarex Inc. (MEDX) | Licensing and distribution agreement for therapeutic rights | IDM will attain the right to use certain therapeutic products developed by Medarex, including MDX-210, MDX-220 and MDX-447; IDM obtained worldwide rights to MDX-210 and more limited rights to the other two products; Medarex increased its equity stake in IDM from 6% to 34% (11/1**) |
|
Immunomedics Inc. (IMMU) | Amgen Inc. (AMGN) | Licensing agreement for a novel cancer therapeutic antibody, epratuzumab, to treat indolent and aggressive non-Hodgkin's lymphoma | Amgen gains the rights to develop and commercialize epratuzumab in North America and Australia; Amgen also will be responsible for commercial manufacturing and will receive rights to second-generation CD22 products; the agreement includes an $18M up-front payment, clinical milestone payments potentially totaling $65M, and royalties; it also provides for one-time sales milestone payments totaling $50M to $225M if and when annual net sales reach $500M to $1B (12/18) |
|
Incyte Genomics Inc. (INCY) | Galapagos Genomics NV* (Netherlands) | Collaboration to conduct functional genomics studies on full-length genes | Galapagos will generate a recombinant ad will generate a recombinant adenoviral library containing full-length genes selected from Incyte's LifeSeq Gold collection for use in discovering and validating gene function; financial terms were ND (11/14) |
|
Incyte Genomics Inc. (INCY) | Sankyo Co. Ltd.* (Japan) | Licensing agreement for Incyte's LifeSeq Gold database | Sankyo gained the rights to LifeSeq, as well as the ZooSeq animal model database, via Incyte's web site (11/30) |
|
LactoFerrin Products Co.* | Manatech Inc.* | Marketing agreement for exclusive worldwide distribution rights for immune-supporting agents | Agreement is for a combination of immune supporting agents, including Prime Colustrum, a mucosal-delivery growth and repair factor containing product harvested from newborn hormone-free dairy cattle; financial terms were ND (10/29) |
|
Lion Bioscience AG (Germany; LEON) | Nestle Research Center (Switzerland) | License agreement for the data integration technology SRS and other technologies | Lion licensed the technology, including its gene and genome annotation system bioScout, the microarray analysis system array-Scout, as well as genomeScout, Lion's genome comparison software (11/2) |
|
Luminex Corp. (LMNX) | Bio-Rad Laboratories Inc. (AMEX: BIO.A, BIO.B) | Strategic partnership to commercialize a system for drug discovery applications based on the LabMAP technology | BioRad has incorporated Luminex's microsphere-based assay technology and reader in an integrated system to allow researchers to easily extract more data from small samples (12/12) |
|
Luminex Corp. (LMNX) | BioSource International (BIOI) | Strategic partnership to develop reagents and assay kits for basic research and drug discovery | The new assay detection system will be based on Luminex's LabMAP technology (12/18) |
|
Luminex Corp. (LMNX) | MiraiBio Inc.* (formerly Hitachi Genetic Systems) | Multiyear distribution agreement to reagents and instrumentation based on Luminex's LabMap technology | MiraiBio has worldwide nonexclusive rights (12/7) |
|
Luminex Corp. (LMNX) | One Lambda Inc.* | Development agreement for human leukocyte antigen-based tissue typing applications | Luminex entered a multiyear strategic partnership with One Lambda, which receives worldwide nonexclusive rights to develop and distribute reagents and instrumentation based on the LabMAP technology in return for making an up-front payment to Luminex and paying royalties (11/10) |
|
Magainin Pharmaceuticals Inc. (MAGN) | Genentech Inc. (NYSE:DNA) | Agreement to terminate the license and collaboration agreement dated April 28, 2000 covering the IL-9 antibody development program and related respiratory technology | The original deal was worth $65.5M to Magainin; Genentech had made an up-front payment of $5.5M in an equity investment (12/18) |
|
|
|
|
|
|
Maxygen Inc. (MAXY) | Integrated Genomics Inc.* | Collaboration allowing Maxygen access to Integrated Genomics' bioinformatics software and databases | Financial terms were not disclosed (12/8) |
|
MDS Proteomics Inc.* | Zyomyx Inc.* | Collaboration agreement to conduct research to prove the use of protein biochips in mass spectrometry-based proteomic studies | MDS purchased an equity stake in Zyomyx for $2.5M as part of Zyomyx' Series D financing; MDS also will provide funding to support research and development (12/18) |
|
Medarex Inc. (MEDX) | Epigen Inc.* | Research, development and marketing collaboration for antibody-based cancer therapeutics | The companies will share equally in pre-clinical and clinical development, as well as commercialization (11/17) |
|
MedImmune Inc. (MEDI) | MGI Pharma Inc. (MOGN) | Asset purchase agreement for Hexalen (altretamine) | MGI Pharma will pay $7.2M, plus royalties on sales for 10 years of the chemotherapeutic agent, which is approved in the U.S. for ovarian cancer, to MedImmune over an 18-month period; MGI Pharma will assume full product responsibilities early in 2001 (11/15) |
|
Mermaid Pharmaceuticals GmbH* (Germany) | Gene Tools LLC* | Research alliance to examine the biological function of the majority of vertebrate genes | Collaboration will combine the Morpholino antisense technology with high-throughput in organismo screening technology in zebrafish (11/29) |
|
Molecular Simulations Inc. (unit of Pharmacopeia Inc.; PCOP) | Abbott Laboratories (NYSE:ABT), Cytoclonal Pharmaceuticals Inc. (CYPH), Emerald Biostructures Inc.*, Exelixis Inc. (EXEL) and Genencor International Inc. (GCOR) | Establishment of a new high-throughput crystallography consortium | Research project is intended to accelerate drug research by developing and validating rapid methods for X-ray structure determination in structural biology (12/6) |
|
Myriad Genetics Inc. (MYGN) | Encore Pharmaceuticals Inc.* | Licensing agreement for the rights to develop, manufacture and market a drug to prevent and treat prostate, colon and other cancers | Myriad acquired the exclusive worldwide rights to MPC-7869 for an up-front equity investment and for several milestones and then royalties (12/8) |
|
Oxford Glyco-Sciences plc (UK; LSE:OGS) | Incyte Genomics Inc (INCY) | Revised alliance to create content for Incyte's LifeExpress product offering | The companies will move from an exclusive profit-sharing arrangement to a nonexclusive contract payment basis; Incyte will retain its rights to market LifeExpress; financial terms were ND (11/7) |
|
Packard BioScience Co. (PBSC) | Xenometrix Inc. (OTC BB:XENO) | Worldwide license agreement for gene expression profiling | The nonexclusive license covers the collection of gene expression profiles using all platforms, including biochips and high-density microarrays (11/14) |
|
Paracelsian Inc. (OTC BB:PRLN) | Triangle Laboratories Inc.* | Strategic partnership agreement joining Paracelsian's dioxin screening Ah Immunoassay with the high-resolution gas chromatography/high-resolution mass spectrometry testing capability of Triangle | The agreement also provides for a later development and worldwide co-marketing deal for the combined system (12/7) |
|
Paradigm Genetics Inc. (PDGM) | Lion Bioscience AG (Germany; LEON) | Five-year strategic alliance to co-develop and co-market a new plant and fungal metabolic profiling database | The database will be used for target identification and validation; the alliance is an expansion to the one initiated in January 2000; the companies will share revenues from the sale of the database, bioinformatics tools and solutions that result from the alliance (11/15) |
|
Paradigm Genetics Inc. (PDGM) | Prionics AG* (Switzerland) | Extended collaboration to co-develop and co-market blood-based diagnostics for the rapid detection of Creutzfeld Jakob disease in humans and bovine encephalopathy in cattle | The parties will continue to share development costs and Paradigm will receive a royalty on any product developed as a result (12/14) |
|
PE Biosystems Group (NYSE:PEB) | Geneva Proteomics Inc.* | Access agreement for Applied's Maldi TOF/TOF mass spectrometer and ICAT reagents | Geneva will deploy the mass spectrometers and reagents with the initial delivery of early access versions of the technologies in the first half of 2001 (11/22) |
|
PPL Therapeutics Inc. (Scotland; LSE:PTH) | Celentis Ltd.* (New Zealand) | Joint venture focused on the production of pharmaceutical and nutraceutical proteins in the milk of transgenic cattle | The initial aim will be the production of a potential multiple sclerosis protein (12/14) |
|
Protein Design Labs Inc. (PDLI) | InterMune Pharmaceuticals Inc. (ITMN) | Agreement in which PDL will humanize an InterMune monoclonal antibody targeted to Pseudomonas aeruginosa | PDL will receive an up-front fee and will be entitled to milestone payments, as well as annual maintenance payments and royalties (11/28) |
|
Protein Sciences Corp.* | HTS Biosystems* | Discovery collaboration to develop novel protein molecules for the drug and diagnostics markets | PSC granted HTS exclusive rights to its protein library, and retained the right to sell all bulk proteins and peptides and affinity molecules (11/30) |
|
Qiagen NV (Netherlands; QGENF) | Luminex Corp. (LMNX) | Strategic alliance to develop a range of consumable kits and assays | The companies will develop the kits and assays using Luminex's LabMAP technology; Luminex received an up-front payment and will receive future royalty payments (11/27) |
|
Regeneron Pharmaceuticals Inc. (REGN) | Shearwater Corp.* | Agreement for the PEGylation of the obesity drug Axokine | Shearwater will use its PEGylation technology to develop a PEGylated form of Axokine in exchange for license fees, royalties and exclusive rights to supply the PEG (polyethylene glycol) reagent (12/4) |
|
Response Genetics Inc.* | Dianon Systems Inc.* | Exclusive third-party U.S. sales and distribution agreement for Response's Danenberg Tumor Profile chemotherapy gudiance system | Dianon made an equity investment in Response of $1M (11/16) |
|
Rosetta Inpharmatics Inc. (RSTA) | Abbott Laboratories (NYSE:ABT) | Agreement focused on investigating the molecular basis of toxicity of compounds in animal and human liver model systems | Each company will fund its efforts; collaboration will use the FlexJet DNA microarray platform, the Resolver Expression Data Analysis product and Abbott's toxicological science expertise (11/30) |
|
Rosetta Inpharmatics Inc. (RSTA) | Gemini Genomics plc (GMNI) | Discovery partnership for identifying and characterizing sets of genes associated with common human disease | Initial research will focus on the analysis of RNA collected from Gemini's clinical populations; each company will fund its respective contributions and will jointly own intellectual property; they intend to commercialize the rights by licensing them to third parties (11/8) |
|
Seattle Genetics Inc.* | ICOS Corp. (ICOS) | Development and manufacturing deal to provide qualified, GMP-grade product for clinical testing | ICOS will provide the product, a monoclonal antibody for cancer therapy; Seattle Genetics retains the rights to commercialize the product; terms were ND (11/9) |
|
Select Therapeutics Inc. (OTC BB:SLPU) | Cytomatrix LLC* | Formation of a joint venture named Cell Science Therapeutics | Cell Science will develop and commercialize novel biopharmaceutical products based on technologies in cell culture, tissue engineering and immunotherapy; the joint venture encompasses all of Cytomatrix's assets and Select's vaccine program (12/13) |
|
SIGA Technologies Inc. (SIGA) | Maxygen Inc. (MAXY) | Research collaboration for the development of novel vaccines | Collaboration will combine SIGA's vaccine delivery system with Maxygen's antigens for generating an immune response (10/30) |
|
Structural Bioinformatics Inc.* | DeNovo Pharmaceuticals Inc.* | Access agreement for multiple therapeutic target classes within SBI's ProMax 3-dimensional protein structure database | Financial terms were not disclosed (11/21) |
|
Syrrx Inc.* | MolSoft LLC* | 10-year strategic alliance to accelerate structure-guided drug discovery | Companies will combine MolSoft's Virtual Lig and Screening technology with Syrrx's high-throughput structural proteomics platform (10/31) |
|
Trega Biosciences Inc. (TRGA) | Tibotec Group N.V.* (Belgium) | Licensing agreement for Trega's iDEA Predictive ADME Simulation System for absorption | Tibotec will use the module in its drug discovery activities, which are focused in the area of HIV and AIDS (12/13) |
|
UroGene SA* (Paris) | SynerGenomics Inc.* (Canada) | Research collaboration for the identification of genes associated with the contraction and progression of prostate cancer | The two-year agreement calls for the two sides to conduct genetic studies of six key chromosomal regions discovered by UroGene; UroGene will retain exclusive owner-ship of all commercial applications of the genes discovered and SynerGenomics will receive service fees, as well as milestone payments (11/1**) |
|
Valentis Inc. (VLTS) | Oxford BioMedica plc* (UK) | Collaboration to develop a new version of the cancer drug MetXia | The new version will be developed by adding polyethylene glycol chains to the drug using PolyMASC Pharmaceuticals plc's viraMASC PEGylation technology; PolyMASC is a unit of Valentis (12/13) |
|
Xoma Ltd. (XOMA) | Allergan Inc.* | Dissolved deal for bactericidal/permeability-increasing protein (BPI) | Allegan chose to give back all rights to ophthalmic anti-infective products containing BPI (11/17) |
|
Zyomyx Inc.* | Cambridge Antibody Technology plc (UK; LSE:CAT) | Development collaboration for high-density protein biochips based on antibody arrays | Companies will jointly develop arrays to detect proteins from complex biological mixtures; financial terms were ND (12/4) |
|
Zyomyx Inc.* | Fujirebio Inc.* (Japan) | Collaboration and licensing agreement to develop protein biochips | Zyomyx will receive funding to support research and development efforts for three years, as well as royalty payments on future sales; Fujirebio receives exclusive commercialization rights in Japan (11/17) |
|
Notes: |
||||
# This chart does not include agreements that involve agricultural product development. |
||||
* Private companies are indicated with an asterisk. ** Denotes the date the item ran in BioWorld International. |
||||
ND = Not disclosed, available or reported. |
||||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. |
||||
AMEX =American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Stock Exchange; CSE = Copenhagen Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange |